• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Life Science Virtual Investor Forum Agenda Announced for September 18th

    9/16/25 11:57:15 AM ET
    $DRMA
    $INM
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRMA alert in real time by email

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Science Virtual Investor Forum to be held September 18th. This event is co-hosted by Zacks SCR.

    Individual investors, institutional investors, advisors, and analysts are invited to attend.

    REGISTER HERE

    It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.

    Please schedule 1x1 meetings here

    "We are excited to highlight today's innovators from the life science sector," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "Our Virtual Investor Conferences empower investors to connect and understand the vision driving these companies firsthand." 

    September 18th

    Eastern

    Time (ET)
    PresentationTicker(s)
    9:30 AM ETAmplia Therapeutics Limited(OTC:INNMF, ASX: ATX))
    10:00 AM ETKelyniam Global, Inc.(OTCID: KLYG)
    10:30 AM ETUnited Health Products, Inc.(OTCQB:UEEC)
    11:00 AM ETPetVivo Holdings, Inc.(OTCQX:PETV)
    11:30 AM ETDermata Therapeutics, Inc.(NASDAQ:DRMA)
    12:00 PM ETHemostemix Inc.(OTCQB:HMTXF, TSXV:HEM)
    12:30 PM ETLipella Pharmaceuticals Inc.(OTCID: LIPO)
    2:00 PM ETInmed Pharmaceuticals Inc.(NASDAQ:INM)
    2:30 PM ETAccustem Sciences Inc.(OTCQB:ACUT)
    3:00 PM ETSigyn Therapeutics Inc.(OTCQB:SIGY)
    4:00 PM ETPercheron Therapeutics Ltd.(OTCID: PERCF | ASX: PER)



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $DRMA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRMA
    $INM
    $PETV

    CompanyDatePrice TargetRatingAnalyst
    InMed Pharmaceuticals Inc.
    $INM
    11/29/2021$6.00Buy
    HC Wainwright & Co.
    PetVivo Holdings Inc.
    $PETV
    10/12/2021$7.00Buy
    ThinkEquity
    Dermata Therapeutics Inc.
    $DRMA
    9/21/2021$14.00Buy
    Brookline Capital
    Dermata Therapeutics Inc.
    $DRMA
    9/14/2021$9.00Buy
    Maxim Group
    More analyst ratings

    $DRMA
    $INM
    $PETV
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by InMed Pharmaceuticals Inc.

    10-K/A - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    10/24/25 4:05:26 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    10/16/25 4:01:12 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PetVivo Holdings Inc.

    SCHEDULE 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    10/14/25 3:43:34 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $DRMA
    $INM
    $PETV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Bathery John Steven

    3 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    10/23/25 7:31:21 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Klompas Neil A

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    10/21/25 1:58:38 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Klompas Neil A

    3 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    10/17/25 8:33:44 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $INM
    $PETV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PetVivo Holdings, Inc. Addresses Veterinary Industry's GEN Z Problem With Breakthrough AI License Agreement

    MINNEAPOLIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID PETVW)), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., an emerging biomedical device company focused on the commercialization of groundbreaking medical products for horses and companion animals, today announced it has entered into an exclusive 10-year white-label licensing agreement with Digital Landia Holding Corp for breakthrough Agentic Pet AI technology. The Agentic Pet AI technology addresses two critical challenges facing the veterinary industry: i) skyrocketing client acquisition costs, and ii) the difficulties in capturing the exploding Gen Z pet parent demographi

    10/21/25 8:00:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Animal Health, Inc. Enters Vendor Partner Agreement with Veterinary Growth Partners to Expand Access to Innovative Veterinary Therapeutics

    MINNEAPOLIS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., a wholly-owned subsidiary of PetVivo Holdings, Inc. (OTCQX:PETV, OTCID PETVW)) and an emerging biomedical device company focused on the commercialization of groundbreaking medical products for horses and companion animals, today announced it has entered into a Vendor Partner Agreement ("Agreement") with Veterinary Growth Partners ("VGP"). Veterinary Growth Partners is a management services organization (MSO) that supports veterinary practices by offering practice management and marketing tools, consulting, and vendor relationships to help them improve efficiency, profitability, and operations. Veterinary Growth Par

    10/16/25 8:00:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF NOTE CONVERSION AGREEMENTS TO EXTINGUISH OVER TWO MILLION DOLLARS OF OUTSTANDING DEBT

    MINNEAPOLIS, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for horses, dogs and other companion animals announced today that the Company has recently entered into note conversion agreements ("Conversion Agreements") with four existing shareholders of the Company to convert the outstanding balances of fourteen promissory notes ("Notes") having an aggregate debt outstanding of $2,018,155 consisting of principal amount of $1.850,000, plus total accr

    9/30/25 11:33:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $DRMA
    $INM
    $PETV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on InMed Pharmaceuticals with a new price target

    HC Wainwright & Co. initiated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    11/29/21 6:20:24 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ThinkEquity initiated coverage on PetVivo Holdings with a new price target

    ThinkEquity initiated coverage of PetVivo Holdings with a rating of Buy and set a new price target of $7.00

    10/12/21 11:03:37 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Brookline Capital initiated coverage on Dermata Therapeutics with a new price target

    Brookline Capital initiated coverage of Dermata Therapeutics with a rating of Buy and set a new price target of $14.00

    9/21/21 10:38:17 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $INM
    $PETV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lai John bought $90,000 worth of shares (150,000 units at $0.60), increasing direct ownership by 13% to 1,288,592 units (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    4/17/24 5:28:07 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Hull Andrew bought $14,625 worth of shares (37,500 units at $0.39), increasing direct ownership by 4,947% to 38,258 units (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    2/22/24 1:38:46 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adams Eric A bought $14,922 worth of shares (41,600 units at $0.36), increasing direct ownership by 1,763% to 43,959 units (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    2/21/24 2:58:17 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $INM
    $PETV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/19/24 3:38:53 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc.

    SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    11/14/24 4:36:01 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $INM
    $PETV
    Financials

    Live finance-specific insights

    View All

    PetVivo Reports Fiscal Q1 2026 Results

    MINNEAPOLIS, MN, US, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX:PETV, OTC ID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported results for its first quarter of fiscal year 2026 ended June 30, 2025. All comparisons are to the previous year first quarter period ending June 30, 2024, unless otherwise noted. The company will hold a conference call today, August 14, 2025, at 5:00 p.m. Eastern time to discuss the results for the quarter, followed by a question-and-answer session (see dial-in information below). Fiscal Q1

    8/14/25 4:40:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Sets Fiscal First Quarter 2026 Conference Call for Thursday, August 14, 2025 at 5:00 p.m. ET

    MINNEAPOLIS, MN, US, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Thursday, August 14, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2025. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question-and-answer period. The Fiscal First Quarter 2026 conference call information is as follows: Date: Thursday, August 14, 2025 Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific t

    8/7/25 12:45:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Reports Fiscal 2025 Results

    MINNEAPOLIS, MN, US, June 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. and its wholly-owned subsidiary PetVivo Animal Health, Inc. (OTCQB:PETV, OTC:PETVW), a leading biomedical company delivering innovative medical therapeutics for equines and companion animals, reported results for its fiscal year ended March 31, 2025. All comparisons are to the previous fiscal year period unless otherwise noted. The company has filed for an extension for the filing of its Form 10-K for the fiscal year ending March 31, 2025, therefore all financial results reported in this press release are unaudited preliminary estimates, and are subject to change. The company will hold a conference call today at

    6/30/25 4:10:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $DRMA
    $INM
    $PETV
    Leadership Updates

    Live Leadership Updates

    View All

    PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing

    Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership group behind 2023 Kentucky Derby winner Mage, and 2022 Dubai World Cup Champion Country Grammer. The partnership centers on the clinical use and promotion of SPRYNG® with OsteoCushion® Technology, PetVivo's cutting-edge intra-articular device designed to support joint health and durability, and Precise PRP™, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians in elite equine athletes. As part of t

    6/6/25 8:00:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Engages Former Dechra North American President, Mike Eldred as Commercial and Operations Advisor

    PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Mike Eldred as the Company's Commercialization and Operations Advisor. His appointment as an Executive Director by the Company's Board of Directors draws upon Mr. Eldred's 30 years of executive experience in animal health and the veterinary industry to ramp up its product development and sales efforts. For the past 20 years, Mr. Eldred served as President of North American Operations for Dech

    1/27/25 9:29:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Engages Another Top Sales Manager, Cindy Gill, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide

    MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. "Cindy's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other veterinary products and her knowledge of clinic operations enables her to prioritize and better address the veterinarians and cli

    10/21/24 9:45:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care